RT Journal Article
SR Electronic
T1 Single-cell RNA sequencing identifies aberrant transcriptional profiles of cellular populations and altered alveolar niche signalling networks in Chronic Obstructive Pulmonary Disease (COPD)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.13.20193417
DO 10.1101/2020.09.13.20193417
A1 M Sauler
A1 JE McDonough
A1 TS Adams
A1 N Kothapalli
A1 JC Schupp
A1 J Nouws
A1 M Chioccioli
A1 N Omote
A1 C Cosme, Jr
A1 S Poli
A1 EA Ayaub
A1 SG Chu
A1 KH Jensen
A1 J Gomez-Villalobos
A1 CJ Britto
A1 MSB Raredon
A1 PN Timshel
A1 N Kaminski
A1 IO Rosas
YR 2020
UL http://medrxiv.org/content/early/2020/09/14/2020.09.13.20193417.abstract
AB Chronic Obstructive Pulmonary Disease (COPD) pathogenesis involves a failure to maintain alveolar homeostasis due to repetitive injury and inflammation. In order to improve our understanding of cell-specific mechanisms contributing to COPD pathogenesis, we analysed single-cell RNA sequencing (scRNAseq) profiles of explanted parenchymal lung tissue from 17 subjects with advanced COPD requiring transplant and 15 control donor lungs. We identified a subpopulation of alveolar type II epithelial cells that uniquely express HHIP and have aberrant stress tolerance profiles in COPD. Amongst endothelial cells, we identified overlapping and unique shifts in transcriptional profiles of endothelial subtypes that may contribute to vascular inflammation and susceptibility to injury. We also identified population composition changes amongst alveolar macrophages. Finally, application of integrative analyses to our scRNAseq data identified cell-specific contributions to COPD heritability and dysfunctional cell-cell communication pathways that occur within the COPD alveolar niche. These findings provide cell type-specific resolution of transcriptional changes associated with advanced COPD that may underlie disease pathogenesis.Competing Interest StatementCompeting interest: N.K. served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira over the last 3 years, reports Equity in Pliant and a grant from Veracyte and non-financial support from MiRagen. Has IP on novel biomarkers and therapeutics in IPF licensed to Biotech. All outside the topic of this paper. E.A.A. and S.G.C. are employed by Novartis. M.S. is a co-inventor on a Yale patent application describing the therapeutic utility of MIF020 in lung disease.Funding StatementThis work was supported by NIH grants K08HL135402, Flight Attendant Medical Research Institute, and Claude D. Pepper Older Americans Independence Center, Yale School of Medicine to M.S. NIH grants R01HL127349, U01HL145567, U01HL122626, and U54HG008540 to N.K, NHLBI P01 HL114501 and support from the Pulmonary Fibrosis Fund to I.O.R., an unrestricted gift from Three Lake Partners to I.O.R and N.K, and by the German Research Foundation (SCHU 3147/1) to J.C.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were approved by Partners Healthcare Institutional Board Review (IRB Protocol 2011P002419).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData has been deposited in the Gene Expression Omnibus (GSE136831) and can be explored using our online portal (www.copdcellatlas.com). https://www.copdcellatlas.com